The $12K Question: How Employers Can Prove GLP-1 ROI

By Pathriva Health · March 21, 2026 · 6 min read

When an employer pays $12,000/year for a GLP-1 prescription and the patient stops taking it at month 6, the employer doesn’t just lose $6,000 in drug spend. They lose the $4,200 in annual healthcare savings that adherent patient would have generated — and they still carry the comorbidity costs that weight loss would have reduced.

The Math

An adherent GLP-1 patient (PDC ≥ 80%) who achieves ≥10% body weight loss generates approximately:

Savings Category	Annual Value	Source
Healthcare cost reduction	$2,800	Cawley et al., J Health Econ 2015
Absenteeism reduction	$1,200	CDC Worksite Health ScoreCard
Disability claim reduction	$2,400	Finkelstein et al., JOEM 2010
Total savings	$6,400
Drug cost	-$12,000	GoodRx market data 2025
Net cost per adherent patient	-$5,600

Wait — that’s negative. The drug costs more than the savings. So where’s the ROI?

The Portfolio Effect

Not every patient needs ≥10% weight loss to generate value. The average adherent patient on semaglutide 2.4mg achieves ~15% weight loss (STEP 1, NEJM 2021), generating proportionally higher savings:

15% weight loss → $4,200 in healthcare savings alone
Comorbidity improvements: A1C drops 1.0-1.5 points (STEP 2), systolic BP drops 5-8 mmHg
Each comorbidity improvement has its own cost reduction

At portfolio level, the breakeven is reached when ~60% of enrolled patients remain adherent for 12+ months. Above 60% adherence, the program generates positive ROI.

What Non-Adherence Actually Costs

For every non-adherent patient:

Wasted drug spend: Average 6 months of drug at $6,000 before discontinuation
Lost savings: $4,200/year in healthcare cost reduction that never materializes
Administrative waste: PA submission, onboarding, care coordination — ~$500 per patient
Weight regain: 67% of patients regain weight within 12 months of discontinuation (Wilding et al., NEJM 2022)
Comorbidity rebound: A1C and BP typically return to baseline within 6 months

Total cost of one non-adherent patient: ~$10,700 (wasted spend + lost savings + admin).

The Employer’s Dilemma

Benefits directors face a classic information asymmetry problem. They can see drug spend (it’s on the pharmacy claims). They can’t see outcomes (weight loss, A1C reduction, adherence rates) because that data lives in the EHR, not the claims system.

Without outcomes data, the CFO sees: “$12,000/year per employee × 400 employees = $4.8M in drug spend.”

With outcomes data, the CFO sees: “$4.8M in drug spend → $2.1M in documented healthcare savings + $800K in productivity gains = $1.9M net cost for 400 healthier employees.”

Same program. Radically different narrative. The difference is measurement.

What Operators Should Measure

PDC by program month — are patients staying adherent over time?
Weight loss distribution — what percentage achieve 5%, 10%, 15% thresholds?
Comorbidity improvement — A1C, BP, lipids trending in right direction?
Cost per quality-adjusted outcome — not cost per prescription, cost per kg lost
Dropout predictors — who’s about to leave, and can you intervene?

The programs that measure these will keep their contracts. The ones that don’t will lose them to programs that do.

Calculate your program’s ROI at pathriva.com/roi. No login required.